Dangerous Drug: Eptifibatide(ep tiff ib’ ah tide)
Integrilin
PREGNANCY CATEGORY B
Drug Classes
Antiplatelet drug
Glycoprotein IIb/IIIa receptor agonist
Therapeutic Actions
Inhibits platelet aggregation by binding to the glycoprotein IIb/IIIa receptor on the platelet, which prevents the binding of fibrinogen and other adhesive ligands to the platelet.
Indications
Treatment of acute coronary syndrome
Prevention of cardiac ischemic complications in patients undergoing elective, emergency, or urgent percutaneous coronary intervention
Contraindications and Cautions
Contraindicated with allergy to eptifibatide, bleeding diathesis, hemorrhagic stroke, active, abnormal bleeding or stroke within 30 days, uncontrolled or severe hypertension, major surgery within 6 wk, dialysis, severe renal impairment, low platelet count.
Use cautiously in the elderly; with pregnancy, lactation, renal insufficiency.
Available Forms
Injection—0.75, 2 mg/mL
Dosages
Adults
Acute coronary syndrome: 180 mcg/kg IV (maximum of 22.6 mg) over 1–2 min as soon as possible after diagnosis, then 2 mcg/kg/min (maximum 15 mg/hr) by continuous IV infusion for up to 72 hr. If patient is to undergo percutaneous coronary intervention, continue for 18–24 hr after the procedure, up to 96 hr of therapy. Reduce infusion dose to 1 mcg/kg/min if serum creatinine is greater than 2 mg/dL.
Percutaneous coronary intervention: 180 mcg/kg IV as a bolus immediately before the procedure, then 2 mcg/kg/min by continuous IV infusion for 18–24 hr. May give a second bolus of 180 mcg/kg 10 min after the first bolus is given.
Pediatric patients
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
